Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from eastern India. (abre una nueva ventana)

Bohara VV, Ray S, Chakrabarti P, Ray SS, Nath UK, Chaudhuri U.

Fuente‎: Hemoglobin 2014;38(1):44-8.

Indexado en‎: PubMed 24144212

DOI‎: 10.3109/03630269.2013.845844

https://www.ncbi.nlm.nih.gov/pubmed/24144212 (abre una nueva ventana)

Hydroxyurea in thalassemia intermedia--a promising therapy. (abre una nueva ventana)

Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP.

Fuente‎: Ann Hematol 2005;84(7):441-6.

Indexado en‎: PubMed 15838670

DOI‎: 10.1007/s00277-005-1026-4

https://www.ncbi.nlm.nih.gov/pubmed/15838670 (abre una nueva ventana)

Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. (abre una nueva ventana)

Italia KY, Jijina FF, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.

Fuente‎: J Clin Pathol 2010;63(2):147-50.

Indexado en‎: PubMed 20154037

DOI‎: 10.1136/jcp.2009.070391

https://www.ncbi.nlm.nih.gov/pubmed/20154037 (abre una nueva ventana)

Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. (abre una nueva ventana)

Karimi M, Borzouee M, Mehrabani A, Cohan N.

Fuente‎: Eur J Haematol 2009;82(3):213-8.

Indexado en‎: PubMed 19077048

DOI‎: 10.1111/j.1600-0609.2008.01192.x

https://www.ncbi.nlm.nih.gov/pubmed/19077048 (abre una nueva ventana)

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. (abre una nueva ventana)

Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S.

Fuente‎: Eur J Haematol 2010;84(1):52-8.

Indexado en‎: PubMed 19799627

DOI‎: 10.1111/j.1600-0609.2009.01356.x

https://www.ncbi.nlm.nih.gov/pubmed/19799627 (abre una nueva ventana)

Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. (abre una nueva ventana)

Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.

Fuente‎: Blood Cells Mol Dis 2000;26(5):453-66.

Indexado en‎: PubMed 11112383

DOI‎: 10.1006/bcmd.2000.0328

https://www.ncbi.nlm.nih.gov/pubmed/11112383 (abre una nueva ventana)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (abre una nueva ventana)

Perrine SP.

Fuente‎: Pediatr Ann 2008;37(5):339-46.

Indexado en‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (abre una nueva ventana)

Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. (abre una nueva ventana)

Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP.

Fuente‎: Ann N Y Acad Sci 2005;1054:250-6.

Indexado en‎: PubMed 16339672

DOI‎: 10.1196/annals.1345.031

https://www.ncbi.nlm.nih.gov/pubmed/16339672 (abre una nueva ventana)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (abre una nueva ventana)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Fuente‎: Acta Haematol 2004;111(4):189-95.

Indexado en‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (abre una nueva ventana)

Efficacy of erythropoietin on dialysis in patients with beta thalassemia minor. (abre una nueva ventana)

Di Iorio B, De Nicola L, Bellizzi V, Minutolo R, Zamboli P, Rubino R, Fuiano G, Conte G.

Fuente‎: Blood Purif 2004;22(5):453-60.

Indexado en‎: PubMed 15359104

DOI‎: 10.1159/000080729

https://www.ncbi.nlm.nih.gov/pubmed/15359104 (abre una nueva ventana)

The role of recombinant human erythropoietin in the treatment of thalassemia. (abre una nueva ventana)

Rachmilewitz EA, Aker M.

Fuente‎: Ann N Y Acad Sci 1998;850:129-38.

Indexado en‎: PubMed 9668535

https://www.ncbi.nlm.nih.gov/pubmed/9668535 (abre una nueva ventana)

Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. (abre una nueva ventana)

Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E.

Fuente‎: Br J Haematol 2011;154(2):281-4.

Indexado en‎: PubMed 21496003

DOI‎: 10.1111/j.1365-2141.2011.08617.x

https://www.ncbi.nlm.nih.gov/pubmed/21496003 (abre una nueva ventana)

The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. (abre una nueva ventana)

Thein SL.

Fuente‎: Blood Rev 2012;26 Suppl 1:S35-9.

Indexado en‎: PubMed 22631042

DOI‎: 10.1016/S0268-960X(12)70011-5

https://www.ncbi.nlm.nih.gov/pubmed/22631042 (abre una nueva ventana)